Company Filing History:
Years Active: 2021-2025
Title: Innovations in Cancer Treatment by Helen Kotanides
Introduction
Helen Kotanides is a prominent inventor based in Norwalk, CT (US). She has made significant contributions to the field of cancer treatment through her innovative research and development of antibodies. With a total of 3 patents to her name, her work focuses on advancing therapeutic options for patients suffering from various types of tumors.
Latest Patents
Among her latest patents, one notable invention is titled "Methods of treating cancer using anti-CD137 antibodies." This invention relates to antibodies that bind to human CD137 and display agonist activity. These antibodies are useful for treating both solid and hematological tumors, either alone or in combination with chemotherapy and ionizing radiation. Another patent, also concerning "Anti-CD137 antibodies," shares similar applications and highlights the potential of these antibodies in cancer therapy.
Career Highlights
Helen Kotanides is currently associated with Eli Lilly and Company, where she continues to push the boundaries of cancer research. Her work has been instrumental in developing new treatment modalities that could significantly improve patient outcomes.
Collaborations
Throughout her career, Helen has collaborated with esteemed colleagues, including Christopher Carl Frye and Michael Dewain Kalos. These partnerships have fostered a collaborative environment that enhances the innovation process.
Conclusion
Helen Kotanides exemplifies the spirit of innovation in the medical field, particularly in cancer treatment. Her contributions through patents and collaborations are paving the way for new therapeutic strategies that hold promise for patients worldwide.